TY - JOUR
T1 - BCG vaccination in patients with severe combined immunodeficiency
T2 - Complications, risks, and vaccination policies
AU - Marciano, Beatriz E.
AU - Huang, Chiung Yu
AU - Joshi, Gyan
AU - Rezaei, Nima
AU - Carvalho, Beatriz Costa
AU - Allwood, Zoe
AU - Ikinciogullari, Aydan
AU - Reda, Shereen M.
AU - Gennery, Andrew
AU - Thon, Vojtech
AU - Espinosa-Rosales, Francisco
AU - Al-Herz, Waleed
AU - Porras, Oscar
AU - Shcherbina, Anna
AU - Szaflarska, Anna
AU - Kiliç, Şebnem
AU - Franco, Jose L.
AU - Gómez Raccio, Andrea C.
AU - Roxo, Persio
AU - Esteves, Isabel
AU - Galal, Nermeen
AU - Grumach, Anete Sevciovic
AU - Al-Tamemi, Salem
AU - Yildiran, Alisan
AU - Orellana, Julio C.
AU - Yamada, Masafumi
AU - Morio, Tomohiro
AU - Liberatore, Diana
AU - Ohtsuka, Yoshitoshi
AU - Lau, Yu Lung
AU - Nishikomori, Ryuta
AU - Torres-Lozano, Carlos
AU - Mazzucchelli, Juliana T L
AU - Vilela, Maria M S
AU - Tavares, Fabiola S.
AU - Cunha, Luciana
AU - Pinto, Jorge A.
AU - Espinosa-Padilla, Sara E.
AU - Hernandez-Nieto, Leticia
AU - Elfeky, Reem A.
AU - Ariga, Tadashi
AU - Toshio, Heike
AU - Dogu, Figen
AU - Cipe, Funda
AU - Formankova, Renata
AU - Nuñez-Nuñez, M. Enriqueta
AU - Bezrodnik, Liliana
AU - Marques, Jose Gonçalo
AU - Pereira, María I.
AU - Listello, Viviana
AU - Slatter, Mary A.
AU - Nademi, Zohreh
AU - Kowalczyk, Danuta
AU - Fleisher, Thomas A.
AU - Davies, Graham
AU - Neven, Bénédicte
AU - Rosenzweig, Sergio D.
PY - 2014
Y1 - 2014
N2 - Background Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (≥1 month) showed an increased prevalence of complications (P =.006) and death caused by BCG-associated complications (P
AB - Background Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (≥1 month) showed an increased prevalence of complications (P =.006) and death caused by BCG-associated complications (P
KW - BCG
KW - hematopoietic stem cell transplant
KW - immune reconstitution syndrome
KW - mycobacteria
KW - newborn screening
KW - Primary immunodeficiency
KW - severe combined immunodeficiency
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=84897136937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897136937&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2014.02.028
DO - 10.1016/j.jaci.2014.02.028
M3 - Article
C2 - 24679470
AN - SCOPUS:84897136937
VL - 133
SP - 1134
EP - 1141
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 4
ER -